Latest P53 Stories
Temptations to exceed the speed limit are always plentiful, but only reckless drivers give in to such impulses.
Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53.
BEVERLY, Mass., April 11, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers, is pleased to announce that their recent poster at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) generated significant interest from major Pharmaceutical companies and numerous investigators.
A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.
Experts from The Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Florida.
New findings by Fox Chase Cancer Center researchers link a common variant of the powerful anticancer gene p53 to increased inflammatory responses following DNA damage.
When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.
Ulcerative colitis (UC) is an inflammatory bowel disease thought to be related to aberrant activation of the immune system in the intestine.
Researchers offer the first evidence that DNA damage can lead to the regulation of inflammatory responses, the body's reaction to injury.
Researchers have identified a new therapeutic target for lung cancer.
- An imitative word; an onomatopoetic word.